Skip to main
HQY

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 9%

Bulls say

HealthEquity is well-positioned in the growing healthcare savings and spending industry, supported by strong account growth and market share gains. The company's investments in automation and AI provide potential for margin expansion, and its long-term outlook and revenue opportunities are compelling. Regulatory tailwinds, including potential expansion of HSA eligibility, could further increase its addressable market, and the company's current valuation presents a potential buying opportunity for investors.

Bears say

HealthEquity is facing several challenges ahead, including competition from other competitors in the market and a slow growth in HSA balances due to a weakening labor market. However, with the company's current initiatives in digitizing the platform and expanding LTV of account holders, as well as the improving regulatory landscape for HSA eligibility expansion, there are opportunities for long-term growth. Additionally, HealthEquity's focus on inorganic growth through acquisitions and leveraging technology, such as AI, for operational efficiency and cost leverage may help drive margin expansion and increase revenue share in the HSA market. Despite some concerns, HealthEquity's above-average combination of revenue growth and EBITDA margins in an expanding market justifies an Outperform rating.

HealthEquity (HQY) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 11 analysts, HealthEquity (HQY) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.